News >

Novel Agents, CAR T Cells Reinvigorate ALL Landscape

Angelica Welch
Published: Wednesday, Apr 04, 2018

Dr Jae Park

Jae H. Park, MD
The field of acute lymphoblastic leukemia (ALL) has experienced a wave of new agents, with the approval of 3 novel therapies in the past year alone.

State of the Science Summit™ on Hematologic Malignancies, Jae H. Park, MD, an assistant attending physician in the Leukemia Service at Memorial Sloan Kettering Cancer Center, discussed novel therapies for patients with ALL. In an interview during the meeting, Park shared his insight on the impact of agents such as blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel.

OncLive: Please provide an overview of your presentation.

Park: I spoke about some of the novel therapy options for adult patents with ALL. I reviewed some of the data published in the last couple years using immunotherapy, such as bispecific antibodies like blinatumomab; antibody-drug conjugates, such as inotuzumab ozogamicin; and CD19-targeted CAR T cells.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x